Pediatric Neuro-Oncology: Challenges and Opportunities

A special issue of Children (ISSN 2227-9067). This special issue belongs to the section "Oncology and Hematology".

Deadline for manuscript submissions: 15 May 2024 | Viewed by 1165

Special Issue Editors

Department of Pediatric Oncology and Hematology, University Children's Hospital in Krakow, Krakow, Poland
Interests: neuro-oncology; brain tumor; pediatric oncology
Instytut "Pomnik - Centrum Zdrowia Dziecka", Warsaw, Poland
Interests: pediatric hematology; pediatric oncology; pediatrics

Special Issue Information

Dear Colleagues,

It is a great pleasure to introduce this Special Issue in pediatric neuro-oncology. Brain tumors represent the most common solid tumors in childhood, accounting for almost 25% of all childhood cancer, second only to leukemia. Over the past decade, there have been significant developments in understanding the biology of these tumors as reflected by the WHO 2021 re-classification. Novel methodologies for evaluating the genetic and epigenetic changes involved in the molecular pathogenesis of these tumors have resulted in the identification of potential molecular targets as well as improved prognostication.

We are pleased to invite you to contribute to this Special Issue “Pediatric Neuro-Oncology: Challenges and Opportunities”. Within our fast-growing scientific field, we would like to endorse researchers in pursuit of visionary and brave endeavors to submit their work, including specialties of clinical, translational, and basic research in neuro-oncology. We welcome manuscripts concerning surgical excellence, promising treatment targets, prognostic and predictive markers, neuroimaging, and combinations thereof, including big data research.

We look forward to receiving your contributions.

Dr. Małgorzata Czogała
Prof. Dr. Bozenna Dembowska-Baginska
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Children is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • neuro-oncology
  • diagnosis
  • treatment
  • pediatric brain tumors
  • childhood brain cancer
  • immunotherapy

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

13 pages, 515 KiB  
Article
Key Questions on the Long-Term Utility of Methylphenidate in Paediatric Brain Tumour Survivorship: A Retrospective Clinical Case Series
by Alexander J. Hagan and Sarah J. Verity
Children 2024, 11(2), 187; https://doi.org/10.3390/children11020187 - 02 Feb 2024
Viewed by 700
Abstract
Methylphenidate has an established role in the management of attention-deficit hyperactivity disorder and attentional deficit secondary to brain injury. Increasingly, methylphenidate is considered for the attentional deficit in paediatric brain tumour survivors. A small number of studies have explored the benefit of methylphenidate [...] Read more.
Methylphenidate has an established role in the management of attention-deficit hyperactivity disorder and attentional deficit secondary to brain injury. Increasingly, methylphenidate is considered for the attentional deficit in paediatric brain tumour survivors. A small number of studies have explored the benefit of methylphenidate in this population; however, studies are of short duration and do not address the impact of medium to long-term use of methylphenidate on intellectual function. We identified six patients who are survivors of a paediatric brain tumour aged 12–18 years with greater than three years of use of methylphenidate for inclusion in a clinical case series. We used this patient cohort to identify key questions to inform a future long-term cohort study. Linear mixed model and reliable change index analyses were performed on the data. Reliable change index analyses showed benefits to working memory (n = 3), processing speed (n = 2), and full-scale IQ (n = 4) performance for some patients. This exploratory case series suggests the potential medium to long-term benefit of methylphenidate in brain tumour survivorship, indicating the need for larger, appropriately powered studies. These patient data, alongside a discussion of learning points from our previously published studies, are used as a conduit for the identification of questions relating to the use of methylphenidate in a paediatric brain tumour. Full article
(This article belongs to the Special Issue Pediatric Neuro-Oncology: Challenges and Opportunities)
Show Figures

Graphical abstract

Back to TopTop